Pharmacotherapeutic targets in Alzheimer's disease
Open Access
- 21 January 2009
- journal article
- review article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 13 (1), 61-86
- https://doi.org/10.1111/j.1582-4934.2008.00595.x
Abstract
• Current pharmacotherapies for the treatment of AD • AD pharmacotherapies targeting τ ‐ Modulators of – kinases or phosphatases ‐ τ aggregation inhibitors (TAIs) • AD pharmacotherapies targeting Aβ ‐ Inhibitors and/or modulators of the secretases ‐ Aβ aggregation inhibitors ‐ Passive or active immunization • The metal hypothesis of AD • AD pharmacotherapies targeting metal ions ‐ Antioxidants ‐ Metal chelators ‐ Metal complexes ‐ Metal‐protein attenuating compounds Abstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder which is characterized by an increasing impairment in normal memory and cognitive processes that significantly diminishes a person's daily functioning. Despite decades of research and advances in our understanding of disease aetiology and pathogenesis, there are still no effective disease‐modifying drugs available for the treatment of AD. However, numerous compounds are currently undergoing pre‐clinical and clinical evaluations. These candidate pharma‐cotherapeutics are aimed at various aspects of the disease, such as the microtubule‐associated τ‐protein, the amyloid‐β (Aβ) peptide and metal ion dyshomeostasis – all of which are involved in the development and progression of AD. We will review the way these pharmacological strategies target the biochemical and clinical features of the disease and the investigational drugs for each category.Keywords
This publication has 428 references indexed in Scilit:
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer DiseaseArchives of Neurology, 2008
- Therapeutics for Alzheimer's Disease Based on the Metal HypothesisNeurotherapeutics, 2008
- Twenty years of metallo-neurobiology: where to now?European Biophysics Journal, 2007
- Redox Reactions of Copper Complexes Formed with Different β-Amyloid Peptides and Their Neuropathalogical RelevanceBiochemistry, 2007
- Oral administration of metal chelator ameliorates motor dysfunction after a small hemorrhage near the internal capsule in ratJournal of Neuroscience Research, 2006
- Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis)Chemical Reviews, 2006
- Clioquinol, a Drug for Alzheimer's Disease Specifically Interfering with Brain Metal Metabolism: Structural Characterization of Its Zinc(II) and Copper(II) ComplexesInorganic Chemistry, 2004
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Reconstitution of γ-secretase activityNature, 2003
- β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activityCell, 1995